4.7 Review

Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report

期刊

LANCET ONCOLOGY
卷 13, 期 1, 页码 E11-E22

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(11)70175-9

关键词

-

类别

资金

  1. American Association for the Study of Liver Disease (AASLD)
  2. American Society of Transplant Surgeons (ASTS)
  3. European Association for the Study of the Liver (EASL)
  4. European-African Hepato-Pancreato-Biliary Association (E-AHPBA)
  5. European Liver and Intestine Transplant Association (ELITA)
  6. International Hepato-Pancreato-Biliary Association (IHPBA)
  7. International Liver Cancer Association (ILCA)
  8. International Liver Transplantation Society (ILTS)
  9. Transplantation Society (TTS)
  10. Bayer HealthCare
  11. Novartis
  12. Astellas
  13. Johnson Johnson
  14. Roche
  15. MSD
  16. AstraZeneca
  17. Nycomed
  18. B Braun
  19. Baxter
  20. MeVis
  21. CAScination
  22. Microsulis Medical
  23. University of Zurich
  24. Liver and Gastro-Intestinal Foundation

向作者/读者索取更多资源

Although liver transplantation is a widely accepted treatment for hepatocellular carcinoma (HCC), much controversy remains and there is no generally accepted set of guidelines. An international consensus conference was held on Dec 2-4, 2010, in Zurich, Switzerland, with the aim of reviewing current practice regarding liver transplantation in patients with HCC and to develop internationally accepted statements and guidelines. The format of the conference was based on the Danish model. 19 working groups of experts prepared evidence-based reviews according to the Oxford classification, and drafted recommendations answering 19 specific questions. An independent jury of nine members was appointed to review these submissions and make final recommendations, after debates with the experts and audience at the conference. This report presents the final 37 statements and recommendations, covering assessment of candidates for liver transplantation, criteria for listing in cirrhotic and non-cirrhotic patients, role of tumour downstaging, management of patients on the waiting list, role of living donation, and post-transplant management.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据